The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Apr. 16, 11:59 AM

Slide #14. Relypsa Secondary Offering

Company: Relypsa (NASDAQ:RLYP)
Date announced: 4/8/2014
Shares Offered: 3,591,836
Date of Pricing: 4/10/2014
Price Per Share: $24.50
Secondary Offering Details: Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $80 million. All of the shares of the common stock to be sold in the offering will be offered by Relypsa. In addition, Relypsa intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. - updated 4/11 - Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 3,591,836 shares of its common stock at a price to the public of $24.50 per share for gross proceeds of approximately $88 million. Relypsa estimates net proceeds from the offering to be approximately $82 million, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Relypsa has granted the underwriters a 30-day option to purchase up to an additional 538,775 shares of common stock.

Relypsa is a clinical development-stage biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Co. has completed its two-part pivotal Phase 3 trial of their product candidate, patiromer, which is also known as RLY5016, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood, which could lead to sudden death.
Open the RLYP Page at The Online Investor »

Company Name:  Relypsa, Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding RLYP:  13
Total Market Value Held by ETFs:  $3.76M
Total Market Capitalization:  $738.00M
% of Market Cap. Held by ETFs:  0.51%

Open the RLYP Page at The Online Investor (in a new window) »

April 16, 2014    11:59 AM Eastern
Quotes delayed 20 minutes

Trade RLYP Now:

Strong Buy (3.87 out of 4)
88th percentile
(ranked higher than approx. 88% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.